USANA Health Sciences, Inc. reported its financial results for the fiscal third quarter ended September 28, 2024, with consolidated net sales reaching $200 million, a 6.2% decrease compared to the prior-year quarter. Diluted EPS for the quarter was $0.56, representing a 5% decline year-over-year, while active customers decreased by 3% to 452,000.
The company updated its fiscal year 2024 outlook, narrowing its consolidated net sales target to $850 million from the previous range of $850 million to $880 million. The diluted EPS outlook was adjusted to $2.45, from the prior range of $2.40 to $2.55, reflecting continued top-line headwinds and cautious consumer sentiment.
Despite these challenges, USANA generated $30 million in operating cash flow during the quarter and maintained a debt-free balance sheet with $365 million in cash and cash equivalents. The company also launched two new products, a Celavive Resurfacing Serum and a Whey Protein Isolate, as part of its product innovation strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.